Geron reported $-3.64M in Net Income for its fiscal quarter ending in March of 2026.





Net Income Change Date
Amgen USD 1.82B 486M Mar/2026
Bio Techne USD 51.05M 13.04M Mar/2026
Cassava Sciences USD -12.54M 1.73M Dec/2025
Cytokinetics USD -206.03M 23M Mar/2026
Esperion Therapeutics USD 61.83M 93.16M Dec/2025
Exelixis USD 210.47M 34.06M Mar/2026
Genmab DKK 31M 370M Dec/2025
Geron USD -3.64M 27.5M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
Incyte USD 303.33M 4.05M Mar/2026
MacroGenics USD -14.16M 30.98M Dec/2025
Novartis USD 3.16B 747M Mar/2026
Novavax USD 17.53M 219.91M Dec/2025